Real Hope For Cancer Patients | Precision Biologics

UNIQUE DISCOVERY PLATFORM

realize our potential

LEARN MORE

We have a platform of patient tumor
derived anticancer vaccines.

THERAPEUTICS

leaders in biotherapeutics

LEARN MORE

Our unique platform, combined with breakthroughs in biotechnology, enable us to produce targeted antibodies that weren’t possible just a few years ago.

COMPANION DIAGNOSTICS

explore our program

LEARN MORE

Our monoclonal antibodies are designed to target the tumor without harming healthy cells.

Precision Biologics is dedicated to improving the lives of cancer patients through its innovative therapeutic and diagnostic products.

SITC 2022 - Posters will be presented in person at the Boston Convention & Exhibition Center on Thursday, November 10th, 2022

DATE: November 9, 2022

Dr. Philip M. Arlen gives presentation on recent NEO-201 clinical development at Biomarkers & Immuno US, 4th Annual Advances in Immuno-Oncology USA Congress, San Diego, CA, October 4, 2022

DATE: October 4, 2022

Precision Biologics, Inc. and National Cancer Institute Collaborators Deliver Poster Presentation at the ASCO Annual Meeting June 5, 2022

DATE: June 5, 2022

Dr. Philip M. Arlen gives Immunotherapy Section Opening Keynote at Festival of Biologics, San Diego, March 9, 2022

DATE: March 9, 2022

Dr. Philip M. Arlen gives scientific presentation at Biomarkers UK: In-Person, November 8, 2021, Manchester, UK

DATE: November 8, 2021

Phase II Clinical Trial NEO-201 in Combination with Pembrolizumab Detailed Study Information

DATE: October 29, 2021

# of people living with cancer in the US

annual # of new cases of cancer in the US

annual # of deaths from cancer in the US

Discover our innovative Leaders.

Meet our Team

Officer, Board Member

Philip Arlen

President and CEO

Officer

Al Tsang

Chief Scientific Officer

Officer

Sharon A. Mavroukakis

RN, MS

Officer

Massimo Fantini

Director R & D

News and Events

Precision Biologics To Deliver Poster Presentations On Clinical And Scientific Programs At Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

BETHESDA, Md.--(BUSINESS WIRE)--Precision Biologics, Inc. (“Precision”), a clinical-stage immunotherapy and targeted oncology company, will present...

SITC 2022 – Posters will be presented in person at the Boston Convention & Exhibition Center on Thursday, November 10th, 2022

Society for the Immunotherapy of Cancer 2022 Annual Meeting, November 8 – 12, Boston, MA,...

Dr. Philip M. Arlen gives presentation on recent NEO-201 clinical development at Biomarkers & Immuno US, 4th Annual Advances in Immuno-Oncology USA Congress, San Diego, CA, October 4, 2022

Dr. Philip M. Arlen gives presentation “Preclinical/Clinical Development of a Neo-Epitope Targeted Monoclonal Antibody for...

Home